Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma

Journal of Clinical Oncology

Volumn 23, Issue 30, 2005, Pages 7614-7620

  Martin, William G ^a   Ristow, Kay M ^a   Habermann, Thomas M ^a   Colgan, Joseph P ^a   Witzig, Thomas E ^a   Ansell, Stephen M ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINCRISTINE; ANTINEOPLASTIC AGENT; DACARBAZINE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; VINBLASTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; DISEASE FREE SURVIVAL; DRUG WITHDRAWAL; FEMALE; HODGKIN DISEASE; HUMAN; INCIDENCE; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; SURVIVAL TIME; TREATMENT OUTCOME; AGE DISTRIBUTION; CANCER STAGING; CHEMICALLY INDUCED DISORDER; CHILD; LUNG DISEASE; MIDDLE AGED; SURVIVAL RATE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CHILD; DACARBAZINE; DOXORUBICIN; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HODGKIN DISEASE; HUMANS; LUNG DISEASES; MALE; MIDDLE AGED; NEOPLASM STAGING; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; VINBLASTINE;

EID: 32944468191     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.02.7243     Document Type: Article

References (21)

1. Longo DL, Young RC, Wesley M, et al: Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 4:1295-1306, 1986
2. Bonadonna G, Zucali R, Monfardini S, et al: Combination chemotherapy of Hodgkin's disease with Adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 36:252-259, 1975
3. Canellos GP, Anderson JR, Propert KJ, et al: Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478-1484, 1992
4. Duggan DB, Petroni GR, Johnson JL, et al: Randomized comparison of ABVD and MOPP/ ABV hybrid for the treatment of advanced Hodgkin's disease: Report of an intergroup trial. J Clin Oncol 21:607-614, 2003
5. Connors JM, Klimo P, Adams G, et al: Treatment of advanced Hodgkin's disease with chemotherapy: Comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: A report from the National Cancer Institute of Canada clinical trials group. J Clin Oncol 15: 1638-1645, 1997
6. Bonadonna G, De Lena M, Monfardini S, et al: Clinical trials with bleomycin in lymphomas and in solid tumors. Eur J Cancer 8:205-215, 1972
7. Blum RH, Carter SK, Agre K: A clinical review of bleomycin: A new antineoplastic agent. Cancer 31:903-914, 1973
8. Diehl V, Franklin J, Pfreundschuh M, et al: Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 348: 2386-2395, 2003
9. Horning SJ, Hoppe RT, Breslin S, et al: Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: Mature results of a prospective clinical trial. J Clin Oncol 20:630-637, 2002
10. Sleijfer S: Bleomycin-induced pneumonitis. Chest 120:617-624, 2001
11. Lewis BM, Izbicki R: Routine pulmonary function tests during bleomycin therapy: Tests may be ineffective and potentially misleading. JAMA 243:347-351, 1980
12. Hasenclever D, Diehl V: A prognostic score for advanced Hodgkin's disease: International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 339:1506-1514, 1998
13. Umezawa H, Ishizuka M, Maeda K, et al: Studies on bleomycin. Cancer 20:891-895, 1967
14. Canellos GP, Duggan D, Johnson J, et al: How important is bleomycin in the Adriamycin + bleomycin + vinblastine + dacarbazine regimen? J Clin Oncol 22:1532-1533, 2004
15. Matthews JH: Pulmonary toxicity of ABVD chemotherapy and G-CSF in Hodgkin's disease: Possible synergy. Lancet 342:988, 1993
16. Onuma T, Holland JF, Masuda H, et al: Microbiological assay of bleomycin: Inactivation, tissue distribution, and clearance. Cancer 33: 1230-1238, 1974
17. Azoulay E, Herigault S, Levame M, et al: Effect of granulocyte colony-stimulating factor on bleomycin-induced acute lung injury and pulmonary fibrosis. Crit Care Med 31:1442-1448, 2003
18. Saxman SB, Nichols CR, Einhorn LH: Pulmonary toxicity in patients with advanced-stage germ cell tumors receiving bleomycin with and without granulocyte colony stimulating factor. Chest 111:657-660, 1997
19. Bastion Y, Coiffier B: Pulmonary toxicity of bleomycin: Is G-CSF a risk factor? Lancet 344: 474, 1994
20. Bastion Y, Reyes F, Bosly A, et al: Possible toxicity with the association of G-CSF and bleomycin. Lancet 343:1221-1222, 1994
21. Dirix LY, Schrijvers D, Druwe P, et al: Pulmonary toxicity and bleomycin. Lancet 344:56, 1994